Search

Your search keyword '"Lip, G."' showing total 87 results

Search Constraints

Start Over You searched for: Author "Lip, G." Remove constraint Author: "Lip, G." Topic myocardial infarction Remove constraint Topic: myocardial infarction
87 results on '"Lip, G."'

Search Results

1. Associations of retinal artery occlusion and retinal vein occlusion to mortality, stroke, and myocardial infarction: a systematic review.

3. Simultaneous computerised activation of the primary percutaneous coronary intervention pathway reduces out-of-hours door-to-balloon time but not mortality.

4. Cardiovascular risk in patients with sleep apnoea with or without continuous positive airway pressure therapy: follow-up of 4.5 million Danish adults.

5. TLR4 expression on monocyte subsets in myocardial infarction.

6. The CD14++CD16+ monocyte subset and monocyte-platelet interactions in patients with ST-elevation myocardial infarction.

7. Differences between South Asians and White Europeans in five year outcome following percutaneous coronary intervention.

8. High-risk myocardial infarction patients appear to derive more mortality benefit from short door-to-balloon time than low-risk patients.

9. The Birmingham Rehabilitation Uptake Maximisation study (BRUM): a randomised controlled trial comparing home-based with centre-based cardiac rehabilitation.

10. Ethnic differences in myocardial infarction in patients with hypertension: effects of diabetes mellitus.

11. The Birmingham Rehabilitation Uptake Maximisation Study (BRUM). Home-based compared with hospital-based cardiac rehabilitation in a multi-ethnic population: cost-effectiveness and patient adherence.

12. Should oral glucose tolerance testing be mandatory following acute myocardial infarction?

13. Plasma haemostatic markers, endothelial function and ambulatory blood pressure changes with home versus hospital cardiac rehabilitation: the Birmingham Rehabilitation Uptake Maximisation Study.

14. Incremental shuttle walking is associated with activation of haemostatic and haemorheological markers in patients with coronary artery disease: the Birmingham rehabilitation uptake maximization study (BRUM).

16. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT): ALL predictable, and no big surprise out of a HAT?

17. Angiogenesis in myocardial infarction. An acute or chronic process?

18. Predictors of attendance at cardiac rehabilitation after myocardial infarction.

19. Unstable angina following acute MI in a patient with bilateral coronary artery fistulae: an unusual presentation of coronary steal?

20. Mortality and quality of life 12 months after myocardial infarction: effects of depression and anxiety.

22. Do depression and anxiety predict recurrent coronary events 12 months after myocardial infarction?

23. Cariporide Aventis.

24. sFlt-1, a potential antagonist for exogenous VEGF.

25. A pilot study of streptokinase-induced endothelial injury and platelet activation following acute myocardial infarction.

26. Myocardial bridging.

27. Effects of depression and anxiety on mortality and quality-of-life 4 months after myocardial infarction.

28. Myocardial infarction complicating hormone replacement therapy in a young woman with normal coronary arteries.

29. Management of patients with myocardial infarction and hypertension.

30. Prothrombin fragment 1+2 is a risk factor for myocardial infarction in treated hypertensive men.

31. Oxidative stress after thrombolysis.

32. Coronary spasm in acute myocardial infarction.

33. Ethnic differences in pre-admission levels of physical activity in patients admitted with myocardial infarction.

34. Recurrent myocardial infarction with angina and normal coronary arteries.

35. A comparative study of risk factors for acute myocardial infarction amongst men of Indo-origin in Trinidad and the UK.

36. Acute myocardial infarction: a rare complication of the thrombotic tendency in nephrotic syndrome.

38. Clinical phenotype classification to predict risk and optimize the management of patients with atrial fibrillation using the Atrial Fibrillation Better Care (ABC) pathway: a report from the COOL-AF registry.

39. Comparative effectiveness and safety of non-vitamin K antagonists for atrial fibrillation in clinical practice:: GLORIA-AF Registry

41. Evolocumab and clinical outcomes in patients with cardiovascular disease

42. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS

43. Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients

44. Outcomes With Edoxaban Versus Warfarin in Patients With Previous Cerebrovascular Events Findings From ENGAGE AF-TIMI 48 (Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48)

45. Stroke and Mortality Risk in Patients With Various Patterns of Atrial Fibrillation: Results From the ENGAGE AF-TIMI 48 Trial (Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48)

46. Linee guida ESC 2015 per il trattamento dei pazienti con aritmie ventricolari e la prevenzione della morte cardiaca improvvisa: Task Force per il Trattamento dei Pazienti con Aritmie Ventricolari e la Prevenzione della Morte Cardiaca Improvvisa della Società Europea di Cardiologia (ESC)

47. Ankle-Brachial Index and cardiovascular events in atrial fibrillation The ARAPACIS Study

48. Antithrombotic therapy in the elderly: expert position paper of the European Society of Cardiology Working Group on Thrombosis

49. Incidence of myocardial infarction and vascular death in elderly patients with atrial fibrillation taking anticoagulants: relation to atherosclerotic risk factors

50. Mon2 predicts poor outcome in ST-elevation myocardial infarction.

Catalog

Books, media, physical & digital resources